Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT06052345 | Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors,…(CIPN-REBECCA) | — | withdrawn | Sep 25, 2023 | Theodoros Foukakis | No accrual | Enrollment / accrual |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to… | — | terminated | Aug 12, 2024 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | N/A | withdrawn | Sep 24, 2024 | Scripps Health | no patients were able to be enrolled | Enrollment / accrual |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT05591092 | Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular… | — | terminated | Oct 24, 2022 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT03164460 | Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in… | Phase 2 | suspended | May 23, 2017 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT05065736 | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase… | Early Phase 1 | terminated | Oct 4, 2021 | Roberto Vargas | Funding unavailable | Funding |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | Phase 2 | terminated | Jun 19, 2019 | Gregory Daniels | Lack of funding | Funding |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | Phase 1 | withdrawn | Mar 3, 2016 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic… | — | withdrawn | Jul 20, 2025 | Addario Lung Cancer Medical Institute | Sponsor/Funder decision | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small… | Phase 2 | terminated | Sep 7, 2018 | Wake Forest University Health Sciences | After interim analysis decided not to move forward with continuing the trial. | Efficacy / futility |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | Phase 1 | withdrawn | Nov 9, 2023 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | withdrawn | Jan 24, 2024 | Fudan University | The study was withdrawn before participant enrollment because the research team decided not to… | Enrollment / accrual |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic… | N/A | suspended | Nov 18, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to… | Phase 1 | suspended | Jan 6, 2023 | National Cancer Institute (NCI) | Other - DLT assessment and phase 2 dose determination | Other (stated, no rule matched) |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent… | Phase 2 | terminated | Oct 8, 2019 | Elevar Therapeutics | The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in…(AIPAC-003) | Phase 2 / Phase 3 | terminated | Feb 28, 2023 | Immutep S.A.S. | Sponsor Decision | Sponsor / business decision |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small…(CT32) | Phase 1 / Phase 2 | terminated | Mar 15, 2021 | Shanghai Junshi Bioscience Co., Ltd. | The company's research strategy was adjusted and the study was terminated | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT01876771 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in… | Phase 2 | suspended | Jun 13, 2013 | AHS Cancer Control Alberta | Study closed to accrual given widespread availability of the similar marketed product,… | Enrollment / accrual |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06586658 | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or… | Early Phase 1 | suspended | Sep 19, 2024 | Shanghai Changzheng Hospital | Modifications to the trial design | Other (stated, no rule matched) |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic… | Phase 2 | terminated | Sep 11, 2015 | Celgene | not stated | Not stated |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT06666218 | Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) | N/A | suspended | Oct 30, 2024 | Fred Hutchinson Cancer Center | Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to… | Enrollment / accrual |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung…(ALERT-lung) | Phase 2 | terminated | Feb 26, 2018 | ETOP IBCSG Partners Foundation | Low recruitment rate | Enrollment / accrual |
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently… | Phase 2 | terminated | Nov 7, 2019 | Sol-Gel Technologies, Ltd. | Terminated early due to low blinded event rate | Other (stated, no rule matched) |
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated… | Phase 2 | terminated | Jun 30, 2008 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized… | Phase 1 / Phase 2 | terminated | May 11, 2017 | Jonsson Comprehensive Cancer Center | Low accrual | Enrollment / accrual |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Phase 2 | terminated | Feb 7, 2018 | Dana-Farber Cancer Institute | Slow accrual, competing studies, and lack of efficacy | Efficacy / futility |
| NCT06060561 | Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy | — | suspended | Sep 29, 2023 | Mayo Clinic | on hold for analysis | Other (stated, no rule matched) |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 14, 2026source: clinicaltrials